epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2025-24-3-114-122epidemiology-2261Research ArticleОБЗОРREVIEWИммунологические и иммуногенетические аспекты вакцинации против кориImmunological and Immunogenetic Aspects of Vaccination against Measleshttps://orcid.org/0000-0002-6447-1122ФомичевВ. И.FomichevV. I.

Виталий Игоревич Фомичев – заведующий консультативно-диагностическим центром, врач-аллерголог-иммунолог

197022, Санкт-Петербург, ул. Профессора Попова, д. 9

+ 7 (812) 670-01-11

Vitalii I. Fomichev – Head of the Consultative and Diagnostic Center, Allergist-Immunologist

9, Professor Popov St., Saint-Petersburg, 197022

+ 7 (812) 670-01-11

fomichev-00@mail.ruhttps://orcid.org/0000-0002-2371-2460ХаритС. М.KharitS. M.

Сусанна Михайловна Харит – д. м. н., профессор, руководитель научно-исследовательского отдела вакцинопрофилактики и поствакцинальной патологии; профессор кафедры инфекционных заболеваний у детей ФП и ДПО

197022, Санкт-Петербург, ул. Профессора Попова

+7 (812) 234-68-55

Susanna M. Kharit – Dr. Sci. (Med.), Professor, Head of the Research Department of Vaccine Prevention and Post-Vaccination Pathology; Professor of the Department of Infectious Diseases in Children

9, Professor Popov St., Saint-Petersburg, 197022

+7 (812) 234-68-55

kharit-s@mail.ruВильницА. А.VilnitsA. A.

Алла Ароновна Вильниц – д. м. н., старший научный сотрудник отдела вакцинопрофилактики и поствакцинальной патологии; доцент кафедры инфекционных заболеваний у детей ФП и ДПО

197022, Санкт-Петербург, ул. Профессора Попова, д. 9

+7 (812) 234-33-10

Alla A. Vilnits – Dr. Sci. (Med.), Senior Researcher, Department of Vaccine Prevention and Post-Vaccination Pathology; Associate Professor, Department of Infectious Diseases in Children

9, Professor Popov St., Saint-Petersburg, 197022

+7 (812) 234-33-10

vilnitz@mail.ruФГБУ Федеральный научно-клинический центр инфекционных болезней ФМБА РоссииРоссияFederal Research and Clinical Center for Infectious DiseasesRussian FederationФГБУ Федеральный научно-клинический центр инфекционных болезней ФМБА России; ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РоссииРоссияFederal Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical UniversityRussian Federation202528072025243114122Copyright © Фомичев В.И., Харит С.М., Вильниц А.А., 20252025Фомичев В.И., Харит С.М., Вильниц А.А.Fomichev V.I., Kharit S.M., Vilnits A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/2261

Актуальность. Корь соответствует критериям заболевания, которое можно искоренить. Тем не менее, достичь устойчивой элиминации этой инфекции пока не удается, и актуальным становится вопрос длительности сохранения поствакцинального противокоревого иммунитета.Цель. Представить в обзоре на основе современных литературных данных особенности иммунного ответа на вакцинацию против кори.Заключение. Понимание особенностей поствакцинального и постинфекционного иммунитета, поиски способа поддержания пожизненного иммунитета у привитых являются важными задачами для достижения цели элиминации кори. Ликвидация кори по-прежнему достижима, для этого требуется увеличение охвата вакцинацией и изучение особенностей индивидуального иммунного ответа для поддержания популяционного иммунитета.

Relevance. Measles meets the criteria for a disease that can be eradicated. However, it has not yet been possible to achieve sustainable elimination of this infection, and the duration of post-vaccination measles immunity is becoming an important issue.Aim. To present in a review based on current literature data the features of the immune response to vaccination against measles.Conclusion. Understanding the characteristics of post-vaccination and post-infection immunity, and finding a way to maintain lifelong immunity in vaccinated individuals, is an important task in achieving the goal of eliminating measles. Elimination of measles is still achievable, it requires increasing the coverage of vaccination and studying the features of the individual immune response to maintain population immunity. Keywords: measles, vaccination, immune response, immunogenetics, MMR, seronegativity, antibodies, HLA.

корьвакцинацияиммунный ответиммуногенетикаMMRсеронегативностьантителаHLAmeaslesvaccinationimmune responseimmunogeneticsMMRseronegativityantibodiesHLAReferencesВОЗ (2020). Стратегия борьбы с корью и краснухой: 2021–2030. Доступно на: https://iris.who.int/handle/10665/339801.[World Health Organization. (2020). Measles and rubella strategic framework: 2021-2030]. Available at: https://iris.who.int/handle/10665/339801.Gogoi M., Martin C.A., Bird P.W., et al. Risk of vaccine preventable diseases in UK migrants: A serosurvey and concordance analysis. Journal of Migration and Health. 2024. Vol. 9. P. 100217.Gogoi M, Martin CA, Bird PW, et al. Risk of vaccine preventable diseases in UK migrants: A serosurvey and concordance analysis. Journal of Migration and Health. 2024;9:100217. doi.org/10.1016/j.jmh.2024.100217Winter A.K., Moss W.J. Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics. Vaccines. 2024. Vol. 12, N7. P. 814.Winter AK, Moss WJ. Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics. Vaccines. 2024 Jul 22;12(7):814. doi.org/10.3390/vaccines12070814Moss W.J., Griffin D.E. What’s going on with measles? Journal of Virology [Internet]. 2024. Vol. 98, N8.Moss WJ, Griffin DE. What’s going on with measles? Levy DE, editor. Journal of Virology [Internet]. 2024;98(8). doi.org/10.1128/jvi.00758-24Brown B., Fricke I., Imarogbe C., et al. Understanding the Measles Virus at 70 Years: From Cellular Mechanisms to Immunisation, 1954-2024. 2024.Brown B, Fricke I, Imarogbe C, et al. Understanding the Measles Virus at 70 Years: From Cellular Mechanisms to Immunisation, 1954-2024. 2024 Jul 16. doi.org/10.32388/nggcj9.4Crowcroft N.S., Minta A.A., Bolotin S., et al. The Problem with Delaying Measles Elimination. Vaccines [Internet]. 2024. Vol. 12, N7. P. 813.Crowcroft NS, Minta AA, Bolotin S, et al. The Problem with Delaying Measles Elimination. Vaccines [Internet]. 2024;12(7):813. doi.org/10.3390/vaccines12070813Locke J., Marinkovic A., Hamdy K., et al. Routine pediatric vaccinations during the COVID-19 pandemic: A review of the global impact. World Journal of Virology [Internet]. 2023. Vol. 12, N5. P. 256–261.Locke J, Marinkovic A, Hamdy K, et al. Routine pediatric vaccinations during the COVID-19 pandemic: A review of the global impact. World Journal of Virology [Internet]. 2023;12(5):256–61. doi.org/10.5501/wjv.v12.i5.256Minta A.A., Ferrari M., Antoni S., et al. Progress Toward Measles Elimination — Worldwide, 2000–2023. MMWR Morbidity and Mortality Weekly Report [Internet]. 2024;Vol. 73, N45. P. 1036–1042.Minta AA, Ferrari M, Antoni S, et al. Progress Toward Measles Elimination — Worldwide, 2000–2023. MMWR Morbidity and Mortality Weekly Report [Internet]. 2024;73(45):1036–42. doi.org/10.15585/mmwr.mm7345a4Muscat M., Ben Mamou M., Reynen-de Kat C., et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines [Internet]. 2024. Vol. 12, N6. P. 696.Muscat M, Ben Mamou M, Reynen-de Kat C, et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines [Internet]. 2024;12(6):696. doi.org/10.3390/vaccines12060696Sanchez D.J. Measles virus: Continued outbreaks while striving for eradication. Virulence [Internet]. 2024. Vol. 15, N1.Sanchez DJ. Measles virus: Continued outbreaks while striving for eradication. Virulence [Internet]. 2024;15(1). doi.org/10.1080/21505594.2024.2386022Seither R., Yusuf O.B., Dramann D., et al. Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten — United States, 2022–23 School Year. MMWR Morbidity and Mortality Weekly Report [Internet]. 2023. Vol. 72, N45. P. 1217–1224.Seither R, Yusuf OB, Dramann D, et al. Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten — United States, 2022–23 School Year. MMWR Morbidity and Mortality Weekly Report [Internet]. 2023;72(45):1217–24. doi.org/10.15585/mmwr.mm7245a2О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2023 году: Государственный доклад. Москва: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2024. – 364 с. Доступно на: https://www.rospotrebnadzor.ru/upload/iblock/fbc/sd3prfszlc9c2r4xbmsb7o3us38nrvpk/Gosudarstvennyy-doklad-_O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsiiv-2023-godu_..pdf. Ссылка активна на 15 декабря 2024.O sostoianii sanitarno-epidemiologicheskogo blagopoluchiia naseleniia v Rossiiskoi Federatsii v 2023 godu. State report. Moscow: Federal Service for the Oversight of Consumer Protection and Welfare, 2024. – 364 с. (In Russ). Available at: https://www.rospotrebnadzor.ru/upload/iblock/fbc/sd3prfszlc9c2r4xbmsb7o3us38nrvpk/Gosudarstvennyy-doklad-_O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2023-godu_..pdf. Accessed: 15 Dec 2024. (In Russ).Measles and Rubella Global Update February 2025 This report is posted on the WHO Immunization data portal. Доступно на: https://immunizationdata.who.int/global?topic=Provisional-measles-and-rubella-data&location[Measles and Rubella Global Update February 2025 This report is posted on the WHO Immunization data portal] https://immunizationdata.who.int/global?topic=Provisionalmeasles-and-rubella-data&locationEuropean Centre for Disease Prevention and Control [Internet]: Measles and Rubella monthly report. Доступно на: https://measles-rubella-monthly.ecdc.europa.eu/.Ссылка активна на 15 декабря 2024.European Centre for Disease Prevention and Control [Internet]: Measles and Rubella monthly report. Available at: https://measles-rubella-monthly.ecdc.europa.eu/. Accessed: 15 Dec 2024.Patel M.K., Orenstein W.A. Classification of global measles cases in 2013–17 as due to policy or vaccination failure: a retrospective review of global surveillance data. The Lancet Global Health [Internet]. 2019. Vol. 7, N3. P. 313–320.Patel MK, Orenstein WA. Classification of global measles cases in 2013–17 as due to policy or vaccination failure: a retrospective review of global surveillance data. The Lancet Global Health [Internet]. 2019;7(3):313–20. doi.org/10.1016/s2214-109x(18)30492-3Топтыгина А. П., Андреев Ю. Ю., Смердова М. А, и др. Сопоставление гуморального иммунного ответа у взрослых, больных корью, и привитых от этой инфекции. Инфекция и иммунитет. 2021. Т.11, №3. C. 517–522.Toptygina AP, Andreev YuYu, Smerdova MA, et al. Sopostavlenie gumoral’nogo immunnogo otveta u vzroslyh, bol’nyh kor’yu, i privityh ot etoj infekcii. Infekciya i immunitet. 2021;11(3):517–22. (In Russ). doi.org/10.15789/2220-7619-chi-1396Топтыгина А. П., Андреев Ю. Ю., Смердова М. А. и др. Формирование гуморального и клеточного иммунитета на коревую вакцину у взрослых. Инфекция и иммунитет. 2020. Т.10, №1. С. 137–144.Toptygina A.P., Andreev YU.YU., Smerdova M.A., et al. Formirovanie gumoral’nogo i kletochnogo immuniteta na korevuyu vakcinu u vzroslyh. Infekciya i immunitet. 2020;10(1):137–44. (In Russ). doi.org/10.15789/2220-7619-foh-1334Ноздрачева А. В., Рыбин В. В., Грицик А. А. и др. Распространенность антител к вирусам кори, краснухи и эпидемическому паротиту у военнослужащих. Военно-медицинский журнал. 2018. Т. 339, №1. С. 66–70.Nozdracheva AV, Rybin VV, Gricik AA, et al. Rasprostranennost’ antitel k virusam kori, krasnuhi i epidemicheskomu parotitu u voennosluzhashchih. Voenno-medicinskij zhurnal. 2018;339(1):66–70. (In Russ).Топтыгина А. П., Смердова М. А., Наумова М. А. и др. Влияние особенностей популяционного иммунитета на структуру заболеваемости корью и краснухой. Инфекция и иммунитет. 2018. Т.8, №3. С. 341–348.Toptygina AP, Smerdova MA, Naumova MA, et al. Vliyanie osobennostej populyacionnogo immuniteta na strukturu zabolevaemosti kor’yu i krasnuhoj. Infekciya i immunitet. 2018;8(3):341–8. (In Russ). doi.org/10.15789/2220-7619-2018-3-341-348Song K., Lee J.M., Lee E.J., et al. Control of a nosocomial measles outbreak among previously vaccinated adults in a population with high vaccine coverage: Korea, 2019. European Journal of Clinical Microbiology & Infectious Diseases [Internet]. 2022. Vol. 41, N3. P. 455–466.Song K, Lee JM, Lee EJ, et al. Control of a nosocomial measles outbreak among previously vaccinated adults in a population with high vaccine coverage: Korea, 2019. European Journal of Clinical Microbiology & Infectious Diseases [Internet]. 2022;41(3):455–66. doi.org/10.1007/s10096-021-04390-4Bianchi F.P., Stefanizzi P., Trerotoli P., et al. Sex and age as determinants of the seroprevalence of anti-measles IgG among European healthcare workers: A systematic review and meta-analysis. Vaccine [Internet]. 2022. Vol. 40, N23. P. 3127–3141.Bianchi FP, Stefanizzi P, Trerotoli P, et al. Sex and age as determinants of the seroprevalence of anti-measles IgG among European healthcare workers: A systematic review and meta-analysis. Vaccine [Internet]. 2022;40(23):3127–41. doi.org/10.1016/j.vaccine.2022.04.016Kim C.J., Bae J.Y., Jun K.I., et al. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines [Internet]. 2021. Vol.9, N5. P. 501.Kim CJ, Bae JY, Jun KI, et al. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines [Internet]. 2021;9(5):501. doi. org/10.3390/vaccines9050501Conis E. Measles and the Modern History of Vaccination. Public Health Reports [Internet]. 2019. Vol. 134, N2. P. 118–125.Conis E. Measles and the Modern History of Vaccination. Public Health Reports [Internet]. 2019;134(2):118–25. doi.org/10.1177/0033354919826558Higgins D.M., O’Leary S.T. A World without Measles and Rubella: Addressing the Challenge of Vaccine Hesitancy. Vaccines [Internet]. 2024. Vol. 12, N6. P. 694.Higgins DM, O’Leary ST. A World without Measles and Rubella: Addressing the Challenge of Vaccine Hesitancy. Vaccines [Internet]. 2024;12(6):694. doi.org/10.3390/vaccines12060694Toptygina A., Grebennikov D., Bocharov G. Prediction of Specific Antibody- and Cell-Mediated Responses Using Baseline Immune Status Parameters of Individuals Received Measles–Mumps–Rubella Vaccine. Viruses [Internet]. 2023. Vol. 15, N2. P. 524.Toptygina A, Grebennikov D, Bocharov G. Prediction of Specific Antibody- and Cell-Mediated Responses Using Baseline Immune Status Parameters of Individuals Received Measles–Mumps–Rubella Vaccine. Viruses [Internet]. 2023;15(2):524. doi.org/10.3390/v15020524Di Pietrantonj C., Rivetti A., Marchione P., et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database of Systematic Reviews [Internet]. 2021. Vol. 2021, N11.Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database of Systematic Reviews [Internet]. 2021;2021(11). doi.org/10.1002/14651858.cd004407.pub5Castiñeiras A.C.P., Sales A.C., Picone C. de M., et al. The decline of measles antibody titers in previously vaccinated adults: a cross-sectional analysis. Revista do Instituto de Medicina Tropical de SãoPaulo [Internet]. 2024. Vol. 66.Castiñeiras ACP, Sales AC, Picone C de M, et al. The decline of measles antibody titers in previously vaccinated adults: a cross-sectional analysis. Revista do Instituto de Medicina Tropical de São Paulo [Internet]. 2024;66. doi.org/10.1590/s1678-9946202466004Wahl B., Pitzer V.E. Expanded Programme on Immunization at 50 years: its legacy and future. The Lancet [Internet]. 2024 Vol. 403, N10441. P. 2265–2267.Wahl B, Pitzer VE. Expanded Programme on Immunization at 50 years: its legacy and future. The Lancet [Internet]. 2024;403(10441):2265–7. doi.org/10.1016/s0140-6736(24)00982-6Gastañaduy P.A., Goodson J.L., Panagiotakopoulos L., et al. Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination. The Journal of Infectious Diseases [Internet]. 2021. Vol. 224. P. 420–428.Gastañaduy PA, Goodson JL, Panagiotakopoulos L, et al. Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination. The Journal of Infectious Diseases [Internet]. 2021;224:420–8. doi.org/10.1093/infdis/jiaa793Hughes S.L., Bolotin S., Khan S., et al. The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – A systematic review. Vaccine [Internet]. 2020. Vol. 38, N3. P. 460–469.Hughes SL, Bolotin S, Khan S, et al. The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – A systematic review. Vaccine [Internet]. 2020;38(3):460–9. doi.org/10.1016/j.vaccine.2019.10.090Bianchi S., Gori M., Fappani C., et al. Characterization of Vaccine Breakthrough Cases during Measles Outbreaks in Milan and Surrounding Areas, Italy, 2017–2021. Viruses [Internet]. 2022. Vol. 14, N5. P. 1068.Bianchi S, Gori M, Fappani C, et al. Characterization of Vaccine Breakthrough Cases during Measles Outbreaks in Milan and Surrounding Areas, Italy, 2017–2021. Viruses [Internet]. 2022;14(5):1068. doi.org/10.3390/v14051068Haralambieva I.H., Kennedy R.B., Ovsyannikova I.G., et al. Current perspectives in assessing humoral immunity after measles vaccination. Expert Review of Vaccines [Internet]. 2018. Vol. 18, N1. P. 75–87.Haralambieva IH, Kennedy RB, Ovsyannikova IG, et al. Current perspectives in assessing humoral immunity after measles vaccination. Expert Review of Vaccines [Internet]. 2018;18(1):75–87. doi.org/10.1080/14760584.2019.1559063Ghafoori F., Mokhtari-Azad T., Foroushani A.R., et al. Assessing seropositivity of MMR antibodies in individuals aged 2–22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran’s National Measles Laboratory. BMC Infectious Diseases [Internet]. 2024. Vol. 24, N1.Ghafoori F, Mokhtari-Azad T, Foroushani AR, et al. Assessing seropositivity of MMR antibodies in individuals aged 2–22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran’s National Measles Laboratory. BMC Infectious Diseases [Internet]. 2024;24(1). doi.org/10.1186/s12879-024-09593-6Zibolenová J., Hudečková H., Chladná Z., et al. Quantification of Waning Immunity After Measles Vaccination—Evidence From a Seroprevalence Study. American Journal of Epidemiology [Internet]. 2023. Vol. 192, N8. P. 1379–1385.Zibolenová J, Hudečková H, Chladná Z, et al. Quantification of Waning Immunity After Measles Vaccination—Evidence From a Seroprevalence Study. American Journal of Epidemiology [Internet]. 2023;192(8):1379–85. doi.org/10.1093/aje/kwad065Quach H.Q., Ratishvili T., Haralambieva I.H., et al. Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model. Scientific Reports [Internet]. 2024. Vol. 14, N1.Quach HQ, Ratishvili T, Haralambieva IH, et al. Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model. Scientific Reports [Internet]. 2024;14(1). doi.org/10.1038/s41598-024-69825-2Bolotin S., Osman S., Hughes S.L., et al. In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases [Internet]. 2022. Vol. 226, N7. P. 1127–1139.Bolotin S, Osman S, Hughes SL, et al. In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases [Internet]. 2022;226(7):1127–39. doi.org/10.1093/infdis/jiac039Schenk J., Abrams S., Theeten H., et al. Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases [Internet]. 2021. Vol. 21, N2. P. 286–295.Schenk J, Abrams S, Theeten H, et al. Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases [Internet]. 2021;21(2):286–95. doi.org/10.1016/s1473-3099(20)30442-4Robert A., Suffel A.M., Kucharski A.J. Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study. The Lancet Public Health [Internet]. 2024. Vol. 9, N10. P. 766–775.Robert A, Suffel AM, Kucharski AJ. Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study. The Lancet Public Health [Internet]. 2024;9(10):766–75. doi.org/10.1016/s2468-2667(24)00181-6Woudenberg T., van Binnendijk R., Veldhuijzen I., et al. Additional Evidence on Serological Correlates of Protection against Measles: An Observational Cohort Study among Once Vaccinated Children Exposed to Measles. Vaccines [Internet]. 2019. Vol. 7, N4. P. 158.Woudenberg T, van Binnendijk R, Veldhuijzen I, et al. Additional Evidence on Serological Correlates of Protection against Measles: An Observational Cohort Study among Once Vaccinated Children Exposed to Measles. Vaccines [Internet]. 2019;7(4):158. doi.org/10.3390/vaccines7040158Wang W., O’Driscoll M., Wang Q., et al. Dynamics of measles immunity from birth and following vaccination. Nature Microbiology [Internet]. 2024. Vol. 9, N7. P. 1676–1685.Wang W, O’Driscoll M, Wang Q, et al. Dynamics of measles immunity from birth and following vaccination. Nature Microbiology [Internet]. 2024;9(7):1676–85. doi.org/10.1038/s41564-024-01694-xQuach H.Q., Chen J., Monroe J.M., et al. The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine. The Journal of Infectious Diseases [Internet]. 2022. Vol. 227, N1. P. 141–150.Quach HQ, Chen J, Monroe JM, et al. The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine. The Journal of Infectious Diseases [Internet]. 2022;227(1):141–50. doi.org/10.1093/infdis/jiac351Haralambieva I.H., Chen J., Quach H.Q., et al. Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine. Frontiers in Immunology [Internet]. 2024. Vol. 15.Haralambieva IH, Chen J, Quach HQ, et al. Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine. Frontiers in Immunology [Internet]. 2024;15. doi.org/10.3389/fimmu.2024.1358477Chan J.C.H., Leung D., Chan S.M., et al. Seroepidemiology of Measles and Rubella Among Hong Kong Young Adults and the Humoral Responses of a Measles-Mumps-Rubella Booster Among Participants With Low Antibody Levels. The Journal of Infectious Diseases [Internet]. 2024. Vol. 230, N6. P. 1367–1375.Chan JCH, Leung D, Chan SM, et al. Seroepidemiology of Measles and Rubella Among Hong Kong Young Adults and the Humoral Responses of a Measles-Mumps-Rubella Booster Among Participants With Low Antibody Levels. The Journal of Infectious Diseases [Internet]. 2024;230(6):1367–75. doi.org/10.1093/infdis/jiae297Kaaijk P., Wijmenga-Monsuur A.J., ten Hulscher H.I. ten, et al. Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults. Vaccines [Internet]. 2022. Vol. 10, N1. P. 132.Kaaijk P, Wijmenga-Monsuur AJ, ten Hulscher HI ten, et al. Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults. Vaccines [Internet]. 2022;10(1):132. doi.org/10.3390/vaccines10010132Lüthy I.A., Kantor I.N.. Sarampión [Measles]. Medicina (B Aires). 2020. Vol. 80, N2. P. 162–168.Lüthy IA, Kantor IN. Sarampión [Measles]. Medicina (B Aires). 2020;80(2):162-168.Laganà A., Visalli G., Di Pietro A., et al. Vaccinomics and adversomics: key elements for a personalized vaccinology. Clinical and Experimental Vaccine Research [Internet]. 2024. Vol. 13, N2. P. 105.Laganà A, Visalli G, Di Pietro A, et al. Vaccinomics and adversomics: key elements for a personalized vaccinology. Clinical and Experimental Vaccine Research [Internet]. 2024;13(2):105. doi.org/10.7774/cevr.2024.13.2.105Omersel J., Karas Kuželički N.. Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. Journal of Clinical Medicine [Internet]. 2020. Vol. 9, N11. P. 3561.Omersel J, Karas Kuželički N. Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. Journal of Clinical Medicine [Internet]. 2020;9(11):3561. doi.org/10.3390/jcm9113561Haslund M.M., Sørensen J.K., Graff Stensballe L. Genetics and measles, mumps and rubella vaccine response in childhood and adolescence—A systematic review. Scandinavian Journal of Immunology [Internet]. 2023. Vol. 97, N6.Haslund MM, Sørensen JK, Graff Stensballe L. Genetics and measles, mumps and rubella vaccine response in childhood and adolescence—A systematic review. Scandinavian Journal of Immunology [Internet]. 2023;97(6). doi.org/10.1111/sji.13266Leidere-Reine A., Kolesova O., Kolesovs A., et al. Seroprevalence of diphtheria and measles antibodies and their association with demographics, self-reported immunity, and immunogenetic factors in healthcare workers in Latvia. Vaccine: X [Internet]. 2022. Vol. 10.Leidere-Reine A, Kolesova O, Kolesovs A, et al. Seroprevalence of diphtheria and measles antibodies and their association with demographics, self-reported immunity, and immunogenetic factors in healthcare workers in Latvia. Vaccine: X [Internet]. 2022;10:100149. doi.org/10.1016/j.jvacx.2022.100149Dudley M.Z., Gerber J.E., Budigan Ni H., et al. Vaccinomics: A scoping review. Vaccine [Internet]. 2023. Vol. 41, N14. P. 2357–2367.Dudley MZ, Gerber JE, Budigan Ni H, et al. Vaccinomics: A scoping review. Vaccine [Internet]. 2023;41(14):2357–67. doi.org/10.1016/j.vaccine.2023.02.009Heath E.I., Rosenberg J.E. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nature Reviews Urology [Internet]. 2020. Vol. 18, N2. P. 93–103.Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nature Reviews Urology [Internet]. 2020;18(2):93–103. doi.org/10.1038/s41585-020-00394-5Kennedy R.B., Ovsyannikova I.G., Palese P., et al. Current Challenges in Vaccinology. Frontiers in Immunology [Internet]. 2020. Vol. 11.Kennedy RB, Ovsyannikova IG, Palese P, et al. Current Challenges in Vaccinology. Frontiers in Immunology [Internet]. 2020;11. doi.org/10.3389/fimmu.2020.01181Brady A.M., El-Badry E., Padron-Regalado E., et al. Serosurveillance for Measles and Rubella. Vaccines [Internet]. 2024. Vol. 12, N7. P. 816.Brady AM, El-Badry E, Padron-Regalado E, et al. Serosurveillance for Measles and Rubella. Vaccines [Internet]. 2024;12(7):816. doi.org/10.3390/vaccines12070816Griffin D.E. Measles immunity and immunosuppression. Current Opinion in Virology [Internet]. 2021. Vol. 46, N9. P. 14.Griffin DE. Measles immunity and immunosuppression. Current Opinion in Virology [Internet]. 2021;46:9–14. doi.org/10.1016/j.coviro.2020.08.002Смердова М. А., Топтыгина А. П., Андреев Ю. Ю. и др. Гуморальный и клеточный иммунитет к антигенам вирусов кори и краснухи у здоровых людей. Инфекция и иммунитет. 2019. Т.9, №3-4. С. 607–611.Smerdova MA, Toptygina AP, Andreev YuYu., et. al. Gumoral’nyj i kletochnyj immunitet k antigenam virusov kori i krasnuhi u zdorovyh lyudej. Infekciya i immunitet. 2019;9(3–4):607–11. (In Russ). doi.org/10.15789/2220-7619-2019-3-4-607-611Kim Y.C., Nam H., Choi J.Y., et al. The third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination. Journal of Infection and Public Health [Internet]. 2023. Vol. 16, N10. P. 1643–1649.Kim YC, Nam H, Choi JY, et al. The third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination. Journal of Infection and Public Health [Internet]. 2023;16(10):1643–9. doi.org/10.1016/j.jiph.2023.08.002Wang L., Haralambieva I.H., Ovsyannikova I.G., et al. Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes. Heliyon [Internet]. 2023. Vol. 9, N12.Wang L, Haralambieva IH, Ovsyannikova IG, et al. Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes. Heliyon [Internet]. 2023;9(12):e22998. doi.org/10.1016/j.heliyon.2023.e22998Yentür S.P., Demirbilek V., Gurses C., et al. Immune alterations in subacute sclerosing panencephalitis reflect an incompetent response to eliminate the measles virus. Meinl E, editor. PLOS ONE [Internet]. 2021. Vol. 16, N1.Yentür SP, Demirbilek V, Gurses C, et al. Immune alterations in subacute sclerosing panencephalitis reflect an incompetent response to eliminate the measles virus. Meinl E, editor. PLOS ONE [Internet]. 2021;16(1):e0245077. doi.org/10.1371/journal.pone.0245077Мамаева Т. А., Железнова Н. В., Бичурина М. А. и др. Оценка возрастной структуры больных корью с первичным и вторичным иммунным ответом за период 2010-2016 гг. в Российской Федерации. Инфекция и иммунитет. 2020. Т.10, №4. C. 717–728.Mamaeva TA, Zheleznova NV, Bichurina MA, et al. Ocenka vozrastnoj struktury bol’nyh kor’yu s pervichnym i vtorichnym immunnym otvetom za period 2010-2016 gg. v Rossijskoj Federacii. Infekciya i immunitet. 2020;10(4):717–28. (In Russ). doi.org/10.15789/2220-7619-eoa-1407

The authors declare that there are no conflicts of interest present.